Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 345 publications
Economic value of ribociclib in early breast cancer in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: July 27, 2026
Prediction of Anthracycline Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study.
Journal: JCO precision oncology
Published: June 24, 2026
Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary.
Journal: Future oncology (London, England)
Published: June 22, 2026
Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.
Journal: Future oncology (London, England)
Published: June 22, 2026
Survivor Perspectives on Artificial Intelligence Integration in Breast Cancer Treatment: A Qualitative Study of Trust, Equity, and Application.
Journal: European journal of breast health
Published: June 19, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
Journal: JCO precision oncology
Published: June 17, 2026
SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.
Journal: The oncologist
Published: May 22, 2026
SERENA-6 and the regulatory limits of radiologic progression in modern oncology.
Journal: Breast cancer research and treatment
Published: May 15, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 24, 2026
Corrigendum to "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer" [The Breast 86 (2026) 104744].
Journal: Breast (Edinburgh, Scotland)
Published: April 05, 2026
Last Updated: 09/26/2026